Evidence map›Paper›PMID 38361028›Full record

ArticleClinical neuroradiology2024

Clinical Outcomes On Tubridge Flow Diverter in Treatmenting Intracranial Aneurysms: a Retrospective Multicenter Registry Study.

Qiang Li, Deyuan Zhu, Nan Lv, Pengfei Yang, Yu Zhou, Rui Zhao, Wenjin Yang, Ming Lv, Tianxiao Li, Wenyuan Zhao and 17 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical neuroradiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 11 institutions in 1 country.

Qiang LiNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Deyuan ZhuDepartment of Neurovascular Disease, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, 200080, Shanghai, China.
Nan LvNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Pengfei YangNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Yu ZhouNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Rui ZhaoNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Wenjin YangNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Ming LvBeijing Tiantan Hospital, Capital Medical University, 100070, Beijing, China.
Tianxiao LiHenan Provincial People's Hospital, 463599, Zhengzhou, China.
Wenyuan ZhaoZhongnan Hospital of Wuhan University, 430071, Wuhan, China.
Tiewei QiThe First Affiliated Hospital, Sun Yat-sen University, 510080, Guangzhou, China.
Weixi JiangXiangya Hospital Central South University, 410008, Changsha, China.
Chuanzhi DuanZhujiang Hospital of Southern Medical University, 510280, Guangzhou, China.
Guangyu ZhaoQilu Hospital of Shandong University, 250012, Jinan, China.
Guoli DuanNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Yina WuNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Qian ZhengNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Zifu LiNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Qiao ZuoNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Dongwei DaiNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Yibin FangDepartment of Neurovascular Disease, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, 200080, Shanghai, China.
Qinghai HuangNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Bo HongNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Yi XuNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China.
Yuxiang GuHuashan Hospital Affiliated to Fudan University, 200020, Shanghai, China.
Sheng GuanThe First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Jianmin LiuNeurovascular Center, Changhai Hospital, Naval Medical University, 168 Changhai Road, 200433, Shanghai, China. chstroke@163.com.ORCID http://orcid.org/0000-0002-3599-8267
Second Military Medical University · CNTongji University · CNCapital Medical University · CNCentral South University · CNFirst Affiliated Hospital of Zhengzhou University · CNFudan University · CNHenan Provincial People's Hospital · CNQilu Hospital of Shandong University · CNSun Yat-sen University · CNWuhan University · CNZhujiang Hospital · CN

Funding

Project of the Shanghai Science and Technology Commission 19DZ1930300
6 · The paper itself

Abstract

purposeIn China, the application of nitinol Tubridge flow diverter (TFD) has become popular for treating intracranial aneurysms (IAs). In this study, we investigated the safety outcomes of the application of TFD for treating IAs in real-world scenarios.

methodsWe retrospectively analyzed aneurysms treated with TFD in 235 centers throughout China between April 2018 and April 2020. The primary endpoint was the event-free survival rate at 12 months, defined as the occurrence of morbidity (spontaneous rupture, intraparenchymal hemorrhage (IPH), ischemic stroke, and permanent cranial neuropathy) or death. Univariate and multivariate analyses were performed to assess the risk factors. A good outcome was defined as a modified Rankin Score (mRS) of 0-2.

resultsWe included 1281 unruptured aneurysms treated with TFD. The overall neurological morbidity and death rates after 12 months were 5.4 and 2.8%, respectively. Ischemic strokes were the most common complication (4.2%, P < 0.001). Cranial neuropathy, IPH, and spontaneous rupture occurred in 0.3%, 0.3%, and 0.5% of aneurysms, respectively. Univariate and multivariate analyses indicated that the male gender, older age, larger aneurysm diameter, and aneurysm located on BA were the independent risk factors for neurologic events. Aneurysm located on BA was the independent risk factor for ischemic strokes. Most patients (1222) had access to the mRS, and 93.2% of them achieved good outcomes.

conclusionTreatment of IAs with TFD was associated with low morbidity and mortality, most of which were ischemic events. Large posterior aneurysms might be associated with a higher complication rate.

trial registrationRetrospectively registered.

Indexed as

Intracranial AneurysmRegistriesAdultAgedAlloysChinaEndovascular ProceduresFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsStentsTreatment OutcomeAlloysnitinolFlow diverterIntracranial aneurysmNeurological complicationsTubridge

Identifiers

PMID38361028
OpenAlexW4391846038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.